Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
-192.40M | -84.66M | -31.48M | -18.73M | -2.94M | EBITDA |
-192.40M | -84.66M | -31.48M | 0.00 | 0.00 | Net Income Common Stockholders |
-177.81M | -71.90M | -29.80M | -19.41M | -3.43M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
198.19M | 236.57M | 110.11M | 10.61M | 1.41M | Total Assets |
205.90M | 251.64M | 114.44M | 11.13M | 1.49M | Total Debt |
0.00 | 0.00 | 0.00 | 0.00 | 4.50M | Net Debt |
-114.09M | -49.30M | -87.70M | -10.61M | 3.09M | Total Liabilities |
14.65M | 10.48M | 166.71M | 34.05M | 5.08M | Stockholders Equity |
191.26M | 241.15M | -52.27M | -22.93M | -3.60M |
Cash Flow | Free Cash Flow | |||
-166.41M | -81.17M | -29.22M | -14.56M | -2.46M | Operating Cash Flow |
-166.31M | -81.17M | -29.22M | -14.56M | -2.46M | Investing Cash Flow |
114.96M | -160.47M | -21.76M | 0.00 | 0.00 | Financing Cash Flow |
116.14M | 203.25M | 128.02M | 23.81M | 3.83M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $1.35B | 9.28 | 23.26% | ― | 13.59% | 15.72% | |
66 Neutral | $1.68B | ― | -9.85% | ― | 56.60% | -403.56% | |
60 Neutral | $1.18B | ― | -23.01% | ― | 168.06% | 44.66% | |
55 Neutral | $920.43M | ― | -82.24% | ― | ― | -106.10% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
41 Neutral | $35.94M | ― | -55.00% | ― | -100.00% | 18.17% | |
32 Underperform | $809.32M | ― | -54.14% | ― | ― | 6.99% |
On March 10, 2025, Mineralys Therapeutics announced positive results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials for lorundrostat, a treatment for uncontrolled or resistant hypertension. Both trials met their primary efficacy endpoints, showing statistically significant reductions in systolic blood pressure and a favorable safety profile, indicating potential for regulatory approval and commercial value.
On February 4, 2025, Mineralys Therapeutics announced the completion of enrollment for its Explore-CKD Phase 2 trial, which evaluates the efficacy and safety of lorundrostat for treating hypertension in patients with CKD and albuminuria. This trial aims to address poorly controlled hypertension, a major cause of renal failure and cardiovascular events, with results expected in the second quarter of 2025. This development marks a significant step in expanding treatment options for high-risk patients, potentially impacting the company’s competitive position in the market.
Mineralys Therapeutics announced that the U.S. FDA has cleared their Investigational New Drug Application for a Phase 2 clinical trial of lorundrostat, aimed at treating moderate-to-severe obstructive sleep apnea (OSA) and hypertension. This trial is expected to begin in the first quarter of 2025 and represents an expansion of lorundrostat’s market potential into OSA, furthering Mineralys’ positioning in the treatment of aldosterone-driven diseases. The study will evaluate the drug’s efficacy in reducing the frequency of apnea-hypopnea episodes and controlling nocturnal hypertension, which could have significant implications for patient health and industry stakeholders.